KR20130061046A - Preparation method for fermented rhodiola rosea using absorbents - Google Patents
Preparation method for fermented rhodiola rosea using absorbents Download PDFInfo
- Publication number
- KR20130061046A KR20130061046A KR1020120098953A KR20120098953A KR20130061046A KR 20130061046 A KR20130061046 A KR 20130061046A KR 1020120098953 A KR1020120098953 A KR 1020120098953A KR 20120098953 A KR20120098953 A KR 20120098953A KR 20130061046 A KR20130061046 A KR 20130061046A
- Authority
- KR
- South Korea
- Prior art keywords
- fermentation
- honggyeongcheon
- extract
- lactic acid
- weight
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title description 26
- 244000042430 Rhodiola rosea Species 0.000 title description 5
- 235000003713 Rhodiola rosea Nutrition 0.000 title description 5
- 239000002250 absorbent Substances 0.000 title description 3
- 230000002745 absorbent Effects 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 88
- 239000004927 clay Substances 0.000 claims abstract description 69
- 239000003463 adsorbent Substances 0.000 claims abstract description 53
- 239000000440 bentonite Substances 0.000 claims abstract description 45
- 229910000278 bentonite Inorganic materials 0.000 claims abstract description 45
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims abstract description 45
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000002253 acid Substances 0.000 claims abstract description 29
- 229920001467 poly(styrenesulfonates) Polymers 0.000 claims abstract description 23
- 239000007787 solid Substances 0.000 claims abstract description 23
- 241000186660 Lactobacillus Species 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 21
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 19
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 14
- 239000003957 anion exchange resin Substances 0.000 claims abstract description 13
- 241000191996 Pediococcus pentosaceus Species 0.000 claims abstract description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 116
- 238000000855 fermentation Methods 0.000 claims description 112
- 230000004151 fermentation Effects 0.000 claims description 112
- 239000004310 lactic acid Substances 0.000 claims description 58
- 235000014655 lactic acid Nutrition 0.000 claims description 58
- 241000894006 Bacteria Species 0.000 claims description 56
- 239000000706 filtrate Substances 0.000 claims description 49
- 239000000047 product Substances 0.000 claims description 41
- 230000002378 acidificating effect Effects 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 37
- 235000002789 Panax ginseng Nutrition 0.000 claims description 25
- 229930182470 glycoside Natural products 0.000 claims description 24
- 150000002338 glycosides Chemical class 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 16
- 239000005909 Kieselgur Substances 0.000 claims description 12
- -1 salidroside glycoside Chemical class 0.000 claims description 7
- 241000192001 Pediococcus Species 0.000 claims description 5
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 abstract description 18
- 241001165494 Rhodiola Species 0.000 abstract description 9
- 241000083902 Rhodiola sachalinensis Species 0.000 abstract description 5
- 241001608472 Bifidobacterium longum Species 0.000 abstract description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 abstract description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 abstract description 2
- 229940009291 bifidobacterium longum Drugs 0.000 abstract description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 abstract description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 abstract 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 abstract 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 abstract 1
- 235000012216 bentonite Nutrition 0.000 description 40
- 238000001179 sorption measurement Methods 0.000 description 30
- 238000011282 treatment Methods 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000036541 health Effects 0.000 description 14
- 235000013376 functional food Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 229910021536 Zeolite Inorganic materials 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000010457 zeolite Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229920001429 chelating resin Polymers 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 235000002639 sodium chloride Nutrition 0.000 description 6
- DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 5
- 150000002989 phenols Chemical class 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 150000004804 polysaccharides Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000274 adsorptive effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 239000002734 clay mineral Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007884 disintegrant Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000004330 tyrosol Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000206761 Bacillariophyta Species 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000186606 Lactobacillus gasseri Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000020299 breve Nutrition 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241001133760 Acoelorraphe Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 241000186012 Bifidobacterium breve Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AEMOLEFTQBMNLQ-DTEWXJGMSA-N D-Galacturonic acid Natural products O[C@@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-DTEWXJGMSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- UBXYXCRCOKCZIT-UHFFFAOYSA-N biphenyl-3-ol Chemical group OC1=CC=CC(C=2C=CC=CC=2)=C1 UBXYXCRCOKCZIT-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 238000010000 carbonizing Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229910052570 clay Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003712 decolorant Substances 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000008235 industrial water Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000010841 municipal wastewater Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000271 synthetic detergent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940033203 vitamin b6 0.5 mg Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 홍경천 발효물의 제조방법에 관한 것이다. 특히 흡착제를 이용하여 홍경천 발효물을 제조하는 방법에 관한 것으로, 제조된 홍경천 발효물은 일반 식품, 기능성 식품 또는 의약이나 화장품의 소재로 활용될 수 있다.
The present invention relates to a method for producing a Honggyeongcheon fermented product. In particular, the present invention relates to a method for preparing fermented red ginseng using fermentation agent, and the fermented red ginseng can be used as a material for general food, functional food, medicine or cosmetics.
홍경천(rhodiola rosea)은 유럽과 아시아의 고산지대에 널리 분포되어 서식하는 식물로서, 신경계통의 자극, 우울증의 감소, 작업능력의 향상, 피로회복, 고산병의 예방 등에 유효한 전통약물로 동유럽과 아시아에 오래전부터 사용되어 왔다. 특히, 백두산 해발 1,800m~2,300m사이의 이끼 긴 원시림 속 자작나무숲과 협곡의 바위틈에서 많이 자라고 있는 다년생 초본 식물로 일교차가 크고 건조하며 산소가 희박하고 자외선이 강한 고산지대의 환경에서도 생존할 수 있는 특수한 적응력을 가지고 있어 고산경천 또는 고산홍경천 등의 별명으로도 불린다. Rhodiola rosea ( Rhodiola rosea ) is a plant widely distributed in the high mountains of Europe and Asia. It is a traditional medicine that is effective in stimulating the nervous system, reducing depression, improving work ability, recovering from fatigue, and preventing altitude sickness. It has been used for a long time. Especially, it is a perennial herbaceous plant that grows a lot in birch forests and mossy rocks in the mossy long-growth forest between 1,800m ~ 2,300m above sea level. It is able to survive in high altitude environment with large crossroads, dry oxygen, thin oxygen and strong UV. Due to its special adaptability, it is also known as the Gosan Gyeongcheon or Gosan Honggyeongcheon.
홍경천의 주요성분은 Salidroside, Tyrosol 및 배당체를 비롯하여 전분, 단백질, 지방, 당분, 플라본류 화합물, 아미노산, 무시원소, 미량의 정유 등을 포함한다. 홍경천의 현대적 연구는 1950년대부터 시작되었다. 일부 인삼을 능가하는 약리작용을 지니고 있는 것으로 알려져 있으며, 인삼이 가진 부작용이 전혀 없는 새로운 약물이라는 것이 증명되어 최근 국내외의 큰 주목을 받고 있다. The main components of Rhodiola saline include Salidroside, Tyrosol and Glycoside, as well as starch, protein, fat, sugar, flavone compounds, amino acids, negligible elements and trace essential oils. Hong's modern research began in the 1950s. It is known to have a pharmacological action that surpasses some ginseng, and has recently been attracting great attention at home and abroad as it has been proved to be a new drug with no side effects.
홍경천의 주요 효능으로는 원기 회복, 장수, 근무력증 예방, 피로회복 등에 유효하다는 보고가 있다. 홍경천의 효과는 최근에 많은 관심 속에 연구가 활발히 진행되고 있고, 특히 홍경천 술, 구보약, 캡슐, 차, 껌, 사탕 등 30여 가지의 다양한 건강기능식품 또는 의약의 소재로서의 가치가 인정되어 제품 개발이 더욱 증가하고 있다.The main effects of honggyeongcheon are reported to be effective in restoring energy, longevity, work force prevention, and fatigue recovery. The effects of hong kyung cheon have been actively researched in recent years, and the product development has been recognized as the value of 30 kinds of health functional foods or medicines such as hong kyung cheon liquor, old medicine, capsule, tea, gum, candy, etc. This is increasing even more.
종래 홍경천 추출물과 관련하여 등록된 특허기술을 살펴보면, 홍경천 추출물을 함유하는 혈중 알콜 농도 저하용 조성물(한국특허 제10-0179087호), 홍경천 추출물을 함유하는 당뇨병 예방 및 치료용 조성물(한국특허 제10-0179088호), 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물(한국특허 제10-0265385호), 고산 홍경천 추출물을 함유하는 간 섬유화 억제 조성물(한국특허 제10-0316790호), 홍경천 뿌리 추출물을 함유한 면역기능강화제 조성물(한국특허 제10-0386809호), 홍경천 추출물을 함유하는 미백조성물(한국특허 제10-0445404호), 홍경천 추출물을 함유하는 바이러스 질환의 예방 및 치료용 조성물(한국특허 제10-999872호)등이 있다. 하지만 상기 특허들은 모두 홍경천 추출물 자체 또는 이를 분획한 분획물의 효능을 확인하고 있을 뿐, 홍경천의 유효성분 중 하나로 알려진 살리드로사이드를 인체에서 흡수되기 용이하도록 배당체에서 비배당체로 생물전환시키는 방법에 대해서는 전혀 알려진 바 없다.Looking at the patent technology registered in relation to the conventional honggyeongcheon extract, a composition for reducing blood alcohol concentration containing honggyeongcheon extract (Korean Patent No. 10-0179087), a composition for preventing and treating diabetes containing honggyeongcheon extract (Korean Patent No. 10 -0179088), honggyeongcheon extract (Korea Patent No. 10-0265385) having a preventive and therapeutic effect of circulatory diseases, liver fibrosis inhibitory composition (Korea Patent No. 10-0316790), containing a high acid honggyeongcheon extract, Hongkyeongcheon root extract Immunostimulating agent composition (Korean Patent No. 10-0386809), whitening composition containing Honggyeongcheon extract (Korean Patent No. 10-0445404), composition for the prevention and treatment of viral diseases containing Honggyeongcheon extract (Korean Patent No. 10-999872). However, all of the above patents only confirm the efficacy of the Rhodiola sac extract itself or the fractions fractionated therefrom, and there is no description of the method of bioconversion from glycoside to non-glycoside to facilitate the absorption of salidroside, which is known as one of the active ingredients of Rhodiola saline, in the human body. None known.
본 발명자들은 인체에 흡수되기에 유리한 살리드로사이드의 비배당체로의 생물전환을 위하여 홍경천 유산균 발효물의 제조방법을 연구하던 중, 단독으로 발효가 거의 진행되지 않는 홍경천 추출물을 특정 흡착제를 처리할 경우 유산균 발효가 진행되어 살리드로사이드의 비배당체 함량 비율이 증진됨을 알게 되어 본 발명을 완성하였다.
The present inventors are studying the preparation method of fermentation products of Honggyeongcheon lactic acid bacteria for bioconversion of salidroside to non-glycoside which is advantageous to be absorbed by the human body. The fermentation proceeded to realize that the ratio of the non-glycoside content of the salidroside was completed the present invention.
본 발명은 단독으로 발효가 어려운 홍경천의 발효방법을 제공함으로써, 인체에 흡수되기에 유리한 살리드로사이드의 비배당체 함량이 높은 홍경천 발효물을 제공하는 것을 목적으로 한다.
An object of the present invention is to provide a fermentation product of the high glycosides of salidroside which is advantageous to be absorbed by the human body by providing a fermentation method of the Honggyeongcheon difficult to ferment alone.
본 발명은 홍경천 추출물을 산성백토, 벤토나이트, 규조토, 활성탄 및 약염기성 음이온교환수지 중에서 선택되는 어느 하나 이상의 흡착제로 처리하는 단계; 및 상기 흡착제에 흡착되지 않은 여액에 유산균을 접종하여 발효시키는 단계를 포함하는 홍경천 발효물의 제조방법을 제공한다.The present invention comprises the steps of treating the Honggyeongcheon extract with at least one adsorbent selected from acidic clay, bentonite, diatomaceous earth, activated carbon and weakly basic anion exchange resin; And it provides a method for producing a fermentation product of Honggyeongcheon comprising inoculating fermentation with lactic acid bacteria in the filtrate not adsorbed to the adsorbent.
본 발명의 홍경천 발효물의 제조방법에서 상기 흡착제는 산성백토 또는 벤토나이트인 것을 특징으로 한다.The adsorbent in the method of preparing the Honggyeongcheon fermentation product of the present invention is characterized in that acidic clay or bentonite.
본 발명의 홍경천 발효물의 제조방법에서 상기 약염기성 음이온교환수지는 Dowex MWA-1인 것을 특징으로 한다.The weakly basic anion exchange resin in the manufacturing method of the fermentation product of Honggyeongcheon is characterized in that the Dowex MWA-1.
본 발명의 홍경천 발효물의 제조방법에서 상기 홍경천 추출물 100 중량부에 대하여 흡착제 5 내지 60 중량부 혼합하는 것을 특징으로 한다.In the manufacturing method of the fermentation product of Honggyeongcheon of the present invention, it is characterized in that 5 to 60 parts by weight of the adsorbent is mixed with respect to 100 parts by weight of the extract.
본 발명의 홍경천 발효물의 제조방법에서 상기 홍경천 추출물의 고형분 함량은 0.1 내지 10 중량%인 것을 특징으로 한다.The solid content of the honggyeongcheon extract in the method of manufacturing the honggyeongcheon fermentation product of the present invention is characterized in that 0.1 to 10% by weight.
본 발명의 홍경천 발효물의 제조방법에서 상기 유산균은 락토바실러스속, 비피도박테리움속 및 페디오코커스속 유산균 중에서 선택되는 어느 하나 이상의 유산균인 것을 특징으로 한다.The lactic acid bacteria in the production method of the fermentation product of Honggyeongcheon is characterized in that any one or more lactic acid bacteria selected from the genus Lactobacillus, Bifidobacterium genus and Pediococcus genus.
본 발명의 홍경천 발효물의 제조방법에서 상기 유산균은 락토바실러스 애시도필러스[KCTC 2182], 비피도박테리움 롱검[ATCC 15707], 비피도박테리움 브레비스[ATCC 15700] 및 페디오코커스 펜토사세우스[KCCM 11088P] 중에서 선택되는 어느 하나 이상의 유산균인 것을 특징으로 한다.Lactic acid bacteria in the preparation method of the fermentation product of the present invention, Lactobacillus ashdophyllus [KCTC 2182], Bifidobacterium long gum [ATCC 15707], Bifidobacterium brevis [ATCC 15700] and Pediococcus pentosaceus It is characterized in that any one or more lactic acid bacteria selected from [KCCM 11088P].
본 발명의 홍경천 발효물의 제조방법에서 상기 발효시키는 단계는 25 내지 40 ℃에서 24 내지 96 시간 수행되는 것을 특징으로 한다.The step of fermentation in the method of manufacturing the Honggyeongcheon fermentation product of the present invention is characterized in that it is carried out at 25 to 40
본 발명은 홍경천 추출물을 산성백토, 벤토나이트, 규조토, 활성탄 및 약염기성 음이온교환수지 중에서 선택되는 어느 하나 이상의 흡착제로 처리한 여액에 유산균을 접종하여 발효시킨 발효물로서, 살리드로사이드 배당체와 비배당체의 합 100 중량부에서 비배당체의 함량이 30 내지 100 중량부인 것을 특징으로 하는 홍경천 발효물을 제공한다.The present invention is a fermentation product obtained by inoculating fermentation of lactic acid bacteria into a filtrate treated with Honggyeongcheon extract from any one selected from acidic clay, bentonite, diatomaceous earth, activated carbon, and weakly basic anion exchange resin. It provides a honggyeongcheon fermentation, characterized in that the content of the non-glycoside in the total 100 parts by weight of 30 to 100 parts by weight.
본 발명은 상기 홍경천 발효물을 포함하는 식품 조성물을 제공한다.
The present invention provides a food composition comprising the honggyeongcheon fermented product.
본 발명은 단독으로 발효가 어려운 홍경천의 발효방법을 제공하고, 또한 본 발명의 방법을 통해 제조된 홍경천 발효물은 인체에 흡수되기에 유리한 살리드로사이드의 비배당체 함량이 높기 때문에 새로운 일반식품, 건강기능식품, 의약이나 화장품의 소재로 활용될 수 있다.
The present invention provides a fermentation method of Honggyeongcheon, which is difficult to ferment alone, and furthermore, since the fermentation product of Honggyeongcheon produced through the method of the present invention has a high content of non-glycosides of salidroside, which is advantageous to be absorbed by the human body, new general food and health It can be used as a material for nutraceutical, medicine or cosmetics.
도 1은 본 발명의 제조예, 실시예 및 비교예에서 사용한 홍경천의 사진이다.
도 2a, 2b, 2c 및 2d는 각각 실험예 1에서 홍경천 추출물 고형분 함량이 0.5 중량%, 1 중량%, 3 중량% 및 5 중량% 일 때의 유산균의 종류 및 배양시간에 따른 pH 변화를 나타낸 그래프이다.
도 3은 실험예 2에서 산성백토 또는 벤토나이트 처리량에 따른 홍경천 추출물을 48시간 흡착시킨 후 측정한 여액의 pH를 나타낸 그래프이다.
도 4는 흡착제를 처리하지 않은 홍경천 추출물(●), 홍경천 추출물의 산성백토 흡착 여액(○), 홍경천 추출물의 Dowex MWA-1 흡착 여액(▼), 홍경천 추출물의 벤토나이트 흡착 여액(△)에 유산균을 접종하여 발효시킨 후 발효시간에 따른 균수변화를 확인한 그래프이다.
도 5는 실험예 3에서 살리드로사이드 및 그 비배당체 표준품, 홍경천 추출물(Con), 산성백토 흡착 여액(1B), 산성백토 흡착 여액의 발효물(1A), Dowex MWA-1 흡착 여액(2B), Dowex MWA-1 흡착 여액의 발효물(2A), Diaion HP-2MG 흡착 여액(3B), Diaion HP-2MG 산성백토 흡착 여액의 발효물(3A), 벤토나이트 흡착 여액(4B), 벤토나이트 흡착 여액의 발효물(4A)의 TLC 분석 결과 사진이다.
도 6a, 6b, 6c 및 6d는 각각 실험예 3에서 살리드로사이드 및 그 비배당체 표준품의 HPLC 크로마토그램, 산성백토로 흡착처리하기 전의 홍경천 추출물의 크로마토그램, 산성백토로 흡착처리한 홍경천 추출물 여액의 크로마토그램, 산성백토로 흡착처리한 홍경천 추출물 여액을 48시간 발효시킨 발효물의 크로마토그램이다.
도 7은 실험예 3에서 홍경천 추출물(Con), 산성백토 흡착 여액(1B), 산성백토 흡착 여액의 발효물(1A), Dowex MWA-1 흡착 여액(2B), Dowex MWA-1 흡착 여액의 발효물(2A), Diaion HP-2MG 흡착 여액(3B), Diaion HP-2MG 산성백토 흡착 여액의 발효물(3A), 벤토나이트 흡착 여액(4B), 벤토나이트 흡착 여액의 발효물(4A)의 살리드로사이드 및 살리드로사이드 비배당체의 함량을 비교하여 나타낸 그래프이다.1 is a photograph of Honggyeongcheon used in Preparation Examples, Examples and Comparative Examples of the present invention.
Figures 2a, 2b, 2c and 2d is a graph showing the pH change according to the type and incubation time of lactic acid bacteria when the solid content of Rhodiola cheoncheon extract in Experimental Example 1 is 0.5% by weight, 1% by weight, 3% by weight and 5% by weight, respectively. to be.
Figure 3 is a graph showing the pH of the filtrate measured after 48 hours of adsorbed Honggyeongcheon extract according to the acidic clay or bentonite throughput in Experimental Example 2.
Figure 4 is lactic acid bacteria in the honggyeongcheon extract (●), honggyeongcheon extract filtrate (○), Dowex MWA-1 adsorption filtrate (▼) of the honggyeongcheon extract, the bentonite adsorption filtrate (△) of the honggyeongcheon extract without adsorbents After inoculation and fermentation, it is a graph confirming the bacterial count according to fermentation time.
Figure 5 shows the salicide side and its non-glycoside standard in Experimental Example 3, Hong Kyungcheon extract (Con), acid clay adsorbed filtrate (1B), fermented product of acid clay adsorbed filtrate (1A), Dowex MWA-1 adsorbed filtrate (2B) , Fermentation of Dowex MWA-1 adsorption filtrate (2A), Diaion HP-2MG adsorption filtrate (3B), fermentation of Diaion HP-2MG acid clay adsorption filtrate (3A), bentonite adsorption filtrate (4B), bentonite adsorption filtrate It is a photograph of the result of TLC analysis of the fermented product (4A).
6A, 6B, 6C, and 6D are HPLC chromatograms of salidroside and its non-glycoside standard in Experimental Example 3, chromatograms of Honggyeongcheon extract before adsorptive treatment with acidic clay, and Hongkwangcheon extract filtrate adsorbed with acidic clay, respectively. Chromatogram, a chromatogram of fermentation obtained by fermenting the filtrate of Hongkyungcheon extract treated with acidic clay for 48 hours.
FIG. 7 shows fermentation of Honggyeongcheon extract (Con), acid clay adsorption filtrate (1B), fermentation product of acid clay adsorption filtrate (1A), Dowex MWA-1 adsorption filtrate (2B), and Dowex MWA-1 adsorption filtrate in Experimental Example 3 Salidroside of water (2A), Diaion HP-2MG adsorption filtrate (3B), fermentation product of Diaion HP-2MG acid clay adsorbent filtrate (3A), bentonite adsorption filtrate (4B), and fermentation product of bentonite adsorption filtrate (4A) And a graph showing a comparison of the content of salicide side glycosides.
본 발명은 산성백토, 벤토나이트, 규조토, 활성탄 및 약염기성 음이온교환수지 중에서 선택되는 어느 하나 이상의 흡착제로 처리하는 단계; 및 상기 흡착제에 흡착되지 않은 여액에 유산균을 접종하여 발효시키는 단계를 포함하는 홍경천 발효물의 제조방법에 관한 것이다.The present invention comprises the steps of treating with at least one adsorbent selected from acidic clay, bentonite, diatomaceous earth, activated carbon and weakly basic anion exchange resin; And inoculating the fermented lactic acid bacteria into the filtrate not adsorbed to the adsorbent.
본 발명에서 산성백토(Fuller's Earth, Acid clay)는 몬모릴로나이트(monmorillonite)계 점토광물로서, 콜로이드성 함수규산알루미늄이고, 엷은 황색의 미세한 분말이다. 본 발명의 산성백토는 1g을 물 50mL를 가하여 현탁시킨 다음 여과한 액의 pH는 3 내지 5이다.Fuller's Earth (Acid clay) in the present invention is a montmorillonite clay mineral, colloidal hydrous aluminum silicate, pale yellow fine powder. The acidic clay of the present invention is suspended by adding 1 g of 50 g of water, and then the pH of the filtrate is 3 to 5.
또한 벤토나이트는 산성백토와 마찬가지로 몬모릴로나이트(monmorillonite)계 점토광물로서, 콜로이드성 함수규산알루미늄이다.Bentonite is a montmorillonite clay mineral, like acidic clay, and is colloidal hydrous aluminum silicate.
상기 산성백토 및 벤토나이트가 흡착제 처리 후 수율이 높고, 유산균의 생육을 억제하는 물질을 흡착하여 홍경천의 발효가 이루어지도록 하는 점에서 바람직하다. 이러한 홍경천 추출물을 발효특성은 모든 흡착제에서 개선되는 것이 아니라, 활성백토, 제올라이트, 알루미늄 옥사이드에서는 발효특성이 전혀 개선되지 않는다.The acidic clay and bentonite are preferable in that the yield is high after the adsorbent treatment, and the fermentation of Honggyeongcheon is performed by adsorbing a substance that inhibits the growth of lactic acid bacteria. Fermentation properties of these extracts are not improved in all adsorbents, but fermentation properties are not improved at all in activated clay, zeolite and aluminum oxide.
또한 규조토(Diatomite)는 규조(diatom)이나 단세포식물의 보호피막(규산질 껍질)으로 이루어진 물질이다. 규조토는 흡착제 처리 후 수율은 매우 높지만, 홍경천을 발효시키는 발효특성이 산성백토나 벤토나이트보다 다소 낮다. In addition, diatomite is a substance composed of a protective film (diatom shell) of diatoms or single cell plants. Diatomaceous earth has a very high yield after adsorbent treatment, but the fermentation characteristics of fermenting red gland are slightly lower than acidic clay or bentonite.
또한 활성탄(Activated carbon)은 톱밥, 목편, 야자나무껍질의 식물성섬유질이나 아탄 또는 석유 등의 함탄소물질을 탄화시킨 다음 활성화시킨 것이다. 활성탄은 상기 산성백토나 벤토나이트와 흡착제 처리 수율이 낮고, 홍경천을 발효시키는 발효특성이 산성백토나 벤토나이트보다 다소 낮다. Activated carbon is also activated by carbonizing carbonaceous materials such as vegetable fiber such as sawdust, wood chips and palm bark, or attan or petroleum. Activated carbon has a low yield of acidic clay or bentonite and adsorbent treatment, and the fermentation properties of fermenting Honggyeongcheon are somewhat lower than acidic clay or bentonite.
또한 약염기성 음이온 교환수지는 음이온을 교환하는 이온교환수지로 3차원으로 축중합한 고분자 모체에 1 내지 3급 아민을 결합시킨 것이다. 약염기성 음이온교환수지는 홍경천을 발효시키는 발효특성이 우수하지만, 산성백토나 벤토나이트와 흡착제 처리 수율이 낮다. 약염기성 음이온교환수지로는 예를 들어 Dowex MWA-1 또는 Diaion HP-2MG가 사용될 수 있다. 반면에 양이온 교환수지 예를 들어 Amberlite IRC-50이나 Amberlite XAD-4 등으로 홍경천 추출물을 흡착시키더라도 홍경천 추출물의 발효 특성을 전혀 개선하지 못한다.The weakly basic anion exchange resin is an ion exchange resin that exchanges anions and combines primary to tertiary amines with a polymer matrix condensed in three dimensions. The weakly basic anion exchange resin has excellent fermentation characteristics for fermenting Honggyeongcheon, but the yield of acidic clay, bentonite and adsorbent is low. As the weakly basic anion exchange resin, for example, Dowex MWA-1 or Diaion HP-2MG can be used. On the other hand, even adsorbing honggyeongcheon extract with a cation exchange resin such as Amberlite IRC-50 or Amberlite XAD-4 does not improve the fermentation properties of honggyeongcheon extract.
본 발명에서 상기 홍경천 추출물을 흡착제로 처리할 때 상기 홍경천 추출물 100 중량부에 대하여 흡착제 5 내지 60 중량부, 바람직하게는 20 내지 50 중량부, 더욱 바람직하게는 25 내지 40 중량부 혼합하는 것이 바람직하다. 흡착제의 함량이 상기 상한치를 초과하면 흡착제의 양이 많아 홍경천 추출물과 흡착제가 고루 혼합되지 않으며, 홍경천 추출물 여액을 분리하기 용이하지 않고, 수율도 저하된다. 또한 흡착제의 비율이 상기 하한치 미만일 경우 유산균 발효를 억제하는 물질의 흡착이 충분치 않아 발효가 충분히 이루어지지 않는다.In the present invention, 5 to 60 parts by weight of the adsorbent, preferably 20 to 50 parts by weight, and more preferably 25 to 40 parts by weight, based on 100 parts by weight of the rhodiola saline extract when treated with the adsorbent. . When the content of the adsorbent exceeds the upper limit, the amount of the adsorbent is large, so that the Hong Kyung-cheon extract and the adsorbent are not evenly mixed, it is not easy to separate the filtrate of the Hong Kyung-cheon extract, and the yield is also lowered. In addition, when the ratio of the adsorbent is less than the lower limit, the adsorption of the substance inhibiting the lactic acid bacteria fermentation is not enough, so that the fermentation is not sufficiently made.
본 발명에서 흡착제 처리 시간이나 온도는 특별히 한정할 필요는 없으나, 처리 시간은 12 시간 이상, 바람직하게는 24 시간 이상, 더욱 바람직하게는 36 내지 54 시간 처리한다. 상기 상한치 이상 흡착제를 처리하더라도 더 이상 발효 특성이 개선되지 않고, 상기 하한치 미만에서는 유산균 발효를 억제하는 물질의 흡착이 충분치 않아 발효가 충분히 이루어지지 않는다. 처리 온도는 5 내지 40 ℃에서 가능하고, 그 이상의 온도에서도 처리가 가능하지만 가온을 통해 흡착효율이 증대되지 않는다.In the present invention, the adsorbent treatment time and temperature need not be particularly limited, but the treatment time is 12 hours or more, preferably 24 hours or more, and more preferably 36 to 54 hours. The treatment of the adsorbent above the upper limit does not improve the fermentation anymore, and below the lower limit, the adsorption of the substance inhibiting the lactic acid bacteria fermentation is not sufficient, so that the fermentation is not sufficiently performed. The treatment temperature is possible at 5 to 40 ° C., and treatment can be performed at higher temperatures, but the adsorption efficiency is not increased through heating.
본 발명의 상기 홍경천과 홍삼의 혼합 추출물에서 홍경천의 고형분 함량은 0.1 내지 10 중량%, 바람직하게는 0.2 내지 5 중량%, 더욱 바람직하게는 0.3 내지 1 중량%로서, 상기 상한치를 초과하는 경우에는 흡착제를 통과하더라도 유산균의 증식 및 발효가 충분히 이루어지지 않고, 상기 하한치 미만에서는 홍경천 유래 유효성분 함량이 감소되어 제조 수율이 낮아 비효율적이다.In the mixed extract of the red ginseng and red ginseng of the present invention, the solid content of the red ginseng is 0.1 to 10% by weight, preferably 0.2 to 5% by weight, more preferably 0.3 to 1% by weight, when the upper limit is exceeded. Even if it passes through, the growth and fermentation of lactic acid bacteria is not sufficiently made, below the lower limit, the content of the active ingredient derived from Honggyeongcheon is reduced and the production yield is inefficient.
본 발명의 홍경천 발효물의 제조에는 락토바실러스속, 비피도박테리움속 및 페디오코커스속 유산균 중에서 선택되는 어느 하나 이상의 유산균이 사용될 수 있다. 바람직하게 상기 유산균은 락토바실러스 애시도필러스, 비피도박테리움 롱검, 비피도박테리움 브레비 스 및 페디오코커스 펜토사세우스이고, 더욱 바람직하게는 한국식품연구원에서 보관중인 락토바실러스 애시도필러스[KCTC 2182], 비피도박테리움 롱검[ATCC 15707], 비피도박테리움 브레비스[ATCC 15700] 및 페디오코커스 펜토사세우스[KCCM 11088P] 중에서 선택되는 어느 하나 이상의 유산균이고, 가장 바람직하게는 락토바실러스 애시도필러스[KCTC 2182], 비피도박테리움 롱검[ATCC 15707]이다.Lactic acid bacteria selected from Lactobacillus genus, Bifidobacterium genus and Pediococcus genus Lactobacillus may be used in the preparation of the fermentation product of Honggyeongcheon. Preferably, the lactic acid bacteria are Lactobacillus ash also filler's, Bifidobacterium ronggeom, Bifidobacterium Brenna non Scotland and Peddie Oh Caucus pen and quarrying three-house, more preferably Lactobacillus ash also filler being held in the Korea Food Research Institute One or more lactic acid bacteria selected from among [KCTC 2182], Bifidobacterium long gum [ATCC 15707], Bifidobacterium brevis [ATCC 15700] and Pediococcus pentosaceus [KCCM 11088P], and most preferably Lactobacillus ashdophyllus [KCTC 2182], Bifidobacterium longgum [ATCC 15707].
본 발명의 홍경천 발효물의 제조방법의 발효시키는 단계는 25 내지 40 ℃에서 24 내지 96 시간 수행된다.The fermentation step of the method for producing a fermentation product of Honggyeongcheon is carried out at 25 to 40 ° C. for 24 to 96 hours.
상기 방법으로 제조된 홍경천 발효물은 살리드로사이드 배당체와 비배당체의 합 100 중량부에서 비배당체의 함량이 30 내지 100 중량부, 바람직하게는 50 내지 100 중량부, 더욱 바람직하게는 70 내지 100 중량부로서 홍경천 추출물에 비하여 인체에 흡수되기 용이한 비배당체를 많이 함유하고 있어 홍경천 고유의 효능을 더욱 증진시킬 수 있다. Hong Kyungcheon fermented product prepared by the above method has a content of non-glycoside in a total of 100 parts by weight of the salidroside glycoside and non-glycoside 30 to 100 parts by weight, preferably 50 to 100 parts by weight, more preferably 70 to 100 parts by weight As a part, since it contains a lot of non-glycosides that are easily absorbed by the human body as compared to the extract, it is possible to further enhance the inherent efficacy.
예를 들어, 본 발명의 홍경천 발효물은 항산화 효과를 나타내고, 근육세포의 산화적 스트레스를 억제하며, 운동능력을 향상시키는 활성을 가지므로, 홍경천과 홍삼의 혼합 추출물에 유산균을 접종하여 발효시킨 발효물을 유효성분으로 하는 식품 조성물을 제조할 수 있다. 상기 식품 조성물은 홍경천 발효물을 유효성분으로 포함하는 피로 회복 및 운동능력 향상용 건강기능식품일 수 있다. For example, the fermented red ginseng of the present invention exhibits an antioxidant effect, inhibits oxidative stress of muscle cells, and has an activity of improving exercise ability, and thus fermented by inoculating fermented lactic acid bacteria into a mixed extract of red ginseng and red ginseng. The food composition which uses water as an active ingredient can be manufactured. The food composition may be a health functional food for fatigue recovery and athletic performance including the honggyeongcheon fermented product as an active ingredient.
본 발명에서 건강기능식품이란, 상기 홍경천 발효물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용시 발생할 수 있는 부작용 등이 없는 장점이 있다. 이와 같이 하여 얻어지는 본 발명의 건강기능식품은, 일상적으로 섭취하는 것이 가능하기 때문에 매우 유용하다. 이와 같은 건강기능식품에 있어서의 홍경천 발효물의 첨가량은, 대상인 건강기능식품의 종류에 따라 달라 일률적으로 규정할 수 없지만, 식품 본래의 맛을 손상시키지 않는 범위에서 첨가하면 되며, 대상 식품에 대하여 통상 0.01 내지 50 중량%, 바람직하기로는 0.1 내지 20 중량%의 범위이다. 또한, 환제, 과립제, 정제 또는 캡슐제 형태의 건강기능식품의 경우에는 통상 0.1 내지 100 중량% 바람직하기로는 0.5 내지 80 중량%의 범위에서 첨가하면 된다. 한 구체예에서, 본 발명의 건강기능식품은 환제, 정제, 캡슐제 또는 음료의 형태일 수 있다.In the present invention, the health functional food is a food prepared by adding the fermentation product of Honggyeongcheon to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, and the like. Means to bring the effect, unlike the general medicine has the advantage that there are no side effects that can occur when taking a long-term use of the drug as a raw material. The health functional food of the present invention thus obtained is very useful because it can be consumed on a daily basis. The amount of fermentation products of Honggyeongcheon fermentation products in such health functional foods cannot be defined uniformly depending on the type of the health functional foods to be applied, but may be added within a range that does not impair the original taste of the food, and is usually 0.01 to the target foods. To 50% by weight, preferably 0.1 to 20% by weight. In addition, in the case of a health functional food in the form of pills, granules, tablets or capsules, it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the dietary supplement of the present invention may be in the form of pills, tablets, capsules or beverages.
본 발명의 건강기능식품은 유효성분으로서 홍경천 발효물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 건강기능식품이 드링크제와 음료류로 제조되는 경우에는 본 발명의 홍경천 발효물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종 식물 추출액 등을 추가로 포함시킬 수 있다.
Health functional food of the present invention as an active ingredient, as well as the fermentation of Honggyeongcheon, may include ingredients that are commonly added during food production, for example, include proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents. do. Examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As flavoring agents, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the health functional food of the present invention is prepared with a drink and a beverage, citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be further included in addition to the fermented product of the red ginseng of the present invention. have.
또한 상기 홍경천 발효물을 유효성분으로 하는 본 발명의 항피로 및 운동장애 치료 및 예방용 약학 조성물을 제조할 수 있다.In addition, the anti-fatigue and movement disorder treatment and prevention of the pharmaceutical composition of the present invention using the honggyeongcheon fermentation may be prepared.
한편, 본 명세서에서 용어 ‘유효성분으로 포함하는’이란 본 발명의 홍경천 발효물의 효능 또는 활성을 달성하는 데 충분한 양을 포함하는 것을 의미한다. 본 발명의 한 구체예에서, 본 발명의 조성물 내에서 홍경천 발효물은 예를 들어, 0.001 mg/kg 이상, 바람직하게는 0.1 mg/kg 이상, 보다 바람직하게는 10 mg/kg 이상, 보다 더 바람직하게는 100 mg/kg 이상, 보다 더욱 더 바람직하게는 250 mg/kg 이상, 가장 바람직하게는 0.1 g/kg 이상 포함된다. 홍경천 발효물은 천연물로서 과량 투여하여도 인체에 부작용이 없으므로 본 발명의 조성물 내에 포함되는 홍경천 발효물의 양적 상한은 당업자가 적절한 범위 내에서 선택하여 실시할 수 있다.On the other hand, the term 'comprising as an active ingredient' in the present specification means that it contains an amount sufficient to achieve the efficacy or activity of the Honggyeongcheon fermentation product of the present invention. In one embodiment of the present invention, the red gyeongcheon fermentation product in the composition of the present invention is, for example, at least 0.001 mg / kg, preferably at least 0.1 mg / kg, more preferably at least 10 mg / kg, even more preferred Preferably at least 100 mg / kg, even more preferably at least 250 mg / kg, most preferably at least 0.1 g / kg. Since the fermented red ginseng has no adverse effects on the human body even when it is excessively administered as a natural product, the upper limit of the amount of the red ginseng ferment contained in the composition of the present invention can be carried out by those skilled in the art.
본 발명의 약학 조성물은 상기 유효 성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.The pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant may include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, lubricants. Agents, flavors and the like can be used.
상기 약학 조성물은 투여를 위해서 상기 기재한 유효 성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제제화할 수 있다.The pharmaceutical composition may be formulated to include one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.
상기 조성물의 제제 형태는 과립제, 산제, 정제, 피복정, 캡슐제, 좌제, 액제, 시럽, 즙, 현탁제, 유제, 점적제 또는 주사 가능한 액제 등이 될 수 있다. 예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효 성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용 가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연 당, 옥수수 감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성 검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐 아세테이트, 소듐 클로라이드 등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸 셀룰로스, 아가, 벤토니트, 잔탄 검 등을 포함한다.Formulation forms of the compositions may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions and the like. For example, for formulation into tablets or capsules, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include but are not limited to natural and synthetic gums such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
액상 용액으로 제제화되는 조성물에 있어서 허용 가능한 약학 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.Acceptable pharmaceutical carriers in compositions formulated in liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like. One or more components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
더 나아가 해당분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화 할 수 있다.Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
본 발명의 약학 조성물은 경구 또는 비경구로 투여할 수 있고, 비경구 투여인 경우에는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등으로 투여할 수 있으며, 바람직하게는 경구 투여이다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, or the like, and preferably, oral administration.
본 발명의 약학 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하며, 보통으로 숙련된 의사는 소망하는 치료 또는 예방에 효과적인 투여량을 용이하게 결정 및 처방할 수 있다. 본 발명의 바람직한 구현예에 따르면, 본 발명의 약학 조성물의 1일 투여량은 0.001-10g/㎏이다.Suitable dosages of the pharmaceutical compositions of the present invention vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to reaction, and usually The skilled practitioner can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.
본 발명의 약학 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 오일 또는 수성 매질중의 용액, 현탁액 또는 유화액 형태이거나 엑스제, 분말제, 과립제, 정제 또는 캅셀제 형태일 수도 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.
The pharmaceutical compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or by incorporating into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
이하, 본 발명을 하기 실시예를 참조하여 더욱 구체적으로 설명하기로 한다. 다만, 하기 실시예는 본 발명의 이해를 돕기 위한 것일 뿐, 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described more specifically with reference to the following examples. However, the following examples are provided only to aid understanding of the present invention, and the scope of the present invention is not limited to the following examples.
제조예Manufacturing example 1: One: 홍경천Honggyeongcheon 단독 Exclusive 발효물의Fermented 제조 Produce
가. 재료end. material
주원료인 홍경천(Rhodiola rosea, 도 1)은 2010년 중국에서 구입하였으며, 미분쇄하여 분쇄기(CyclotecTM 1093, FOSS Co., Denmark)로 분말화하여 사용하였다. 홍삼은 시중에 판매되고 있는 홍삼분말(NH 한삼인, 6년근)을 사용하였다.The main raw material, Rhodiola rosea ( Rhodiola rosea , Fig. 1) was purchased in 2010 in China, was pulverized and used by pulverization (Cyclotec ™ 1093, FOSS Co., Denmark). Red ginseng used commercially available red ginseng powder (NH Hansamin, 6 years old).
본 실험에 사용된 균주는 표 1과 같이 한국식품연구원에 보관중인 Lactobacillus, Pediococcus 및 Bifidobacterium 속의 유산균 10종을 이용하였다. 균주는 멸균된 50% 글리세롤에 배양액을 현탁하여 -70 ℃ deep freezer에 장기보관 하였다.The strains used in this experiment are Lactobacillus and Pediococcus stored in the Korea Food Research Institute as shown in Table 1. And Ten lactic acid bacteria of Bifidobacterium spp. Were used. The strain was cultured in sterile 50% glycerol and stored for a long time in a -70 ℃ deep freezer.
나. 홍경천 추출물의 제조I. Preparation of Honggyeongcheon Extract
홍경천 추출물은 환류추출기에 홍경천과 증류수를 함께 넣은 뒤 90 ℃, 3시간 동안 가열하여 나온 추출액을 4 ℃로 조절된 원심분리기(Mega 17R, Hanil Science Indusrrial Co. Ltd., Korea)에서 분리하였다. 분리한 상등액은 여과지(Watman No. 2)로 여과한 다음 여액을 홍경천 추출물로 이용하였다.
Hongkyeongcheon extract was added to the reflux extractor and distilled water at 90 ℃, the extract was heated for 3 hours was separated from the centrifuge (Mega 17R, Hanil Science Indusrrial Co. Ltd., Korea) adjusted to 4 ℃. The separated supernatant was filtered through a filter paper (Watman No. 2), and the filtrate was used as an extract of Honggyeongcheon.
다. 홍경천 발효물의 제조All. Preparation of fermented red pepper
홍경천 추출물의 고형분 함량이 0.5, 1, 3 및 5 중량%가 되도록 희석한 후 희석한 홍경천 추출물을 121 ℃, 1.5기압, 15분간 멸균하였다.After diluting so that the solid content of the honggyeongcheon extract is 0.5, 1, 3 and 5% by weight, the diluted honggyeongcheon extract was sterilized at 121 ° C., 1.5 atm for 15 minutes.
상기 표 1의 유산균을 각각 MRS broth와 GAM broth를 이용하여 20시간, 37 ℃에서 정치 배양하여 활성화시킨 후, 유산균을 배양액 1 중량%(106 CFU/㎖)를 상기 홍경천 추출물에 각각 접종하여 37 ℃에서 48시간 동안 배양하여 홍경천 단독 발효물을 제조하였다.
The lactic acid bacteria of Table 1 were activated by culturing at 37 ° C. for 20 hours using MRS broth and GAM broth, respectively, and then lactic acid bacteria were inoculated with 1 wt% (10 6 CFU / mL) of the culture broth, respectively. Cultured at 48 ℃ for 48 hours to prepare a fermentation of Honggyeongcheon alone.
실험예Experimental Example 1: One: 홍경천Honggyeongcheon 단독 Exclusive 발효물의Fermented 발효특성 확인 Fermentation Characteristics Check
제조예 1의 홍경천 추출물 단독 발효물의 발효특성을 확인하기 위하여, 접종 후 24 및 48시간째에 발효물의 pH 및 생균수의 변화를 확인하였다. In order to confirm the fermentation characteristics of the fermentation product of Honggyeongcheon extract of Preparation Example 1, the pH and viable cell number of fermented products were checked at 24 and 48 hours after inoculation.
생균수는 생균수는 시료 1ml를 멸균 생리식염수 9ml에 희석하고 잘 섞은 후 단계별로 희석한 다음 0.1ml을 취하여 Lactobacillus속, Pediococcus속은 MRS agar에 도말하고, Bifidobacterium속은 5%의 horse blood를 함유한 BL agar에 도말하여 anaerobic jar (BBL Gas Pak Anaerobic System)를 이용하여 최대한 혐기적인 상태로 보관하여 37 ℃에서 24~48시간 배양한 후 생성된 집락수를 계측하고, 그 평균 집락 수에 희석배수를 곱하여 배양액 당 colony를 산출하였다.
The number of viable cells is 1 ml of the sample in 9 ml of sterile physiological saline and mixed well. After diluting step by step, 0.1 ml is taken. Smear agar and store it as anaerobic as possible using anaerobic jar (BBL Gas Pak Anaerobic System), incubate at 37 ℃ for 24 ~ 48 hours, measure the number of colonies produced, multiply the average number of colonies by dilution factor Colony per culture was calculated.
가. 홍경천 추출물 고형분 함량 및 유산균 종류에 따른 pH 변화end. PH Change According to Solid Contents and Types of Lactic Acid Bacteria
홍경천 추출물 고형분 함량이 0.5 중량%, 1 중량%, 3 중량% 및 5 중량% 일 때의 유산균의 종류 및 배양시간에 따른 pH 변화를 도 2a, 2b, 2c 및 2d에 각각 나타내었다.The changes in pH according to the type and incubation time of the lactic acid bacteria when the content of the honggyeongcheon extract solid content is 0.5% by weight, 1% by weight, 3% by weight and 5% by weight are shown in FIGS. 2A, 2B, 2C and 2D, respectively.
도 2a에서 홍경천 추출물의 고형분 함량이 0.5 중량%일 때 초기 pH는 6.25이었으며, 48시간 후 최종 pH 값은 5.25 내지 5.50으로 감소하는 것으로 나타났다.In FIG. 2a, the initial pH was 6.25 when the solid content of the Honggyeongcheon extract was 0.5% by weight, and after 48 hours, the final pH value was decreased from 5.25 to 5.50.
도 2b에서 홍경천 추출물의 고형분 함량이 1 중량%일 때 초기 pH는 6.21이었으며, 48시간 후 최종 pH 값은 5.61 내지 5.70으로 0.5 중량%보다는 다소 적은 폭이지만 감소하는 것으로 나타났다. In FIG. 2B, the initial pH was 6.21 when the solid content of the honggyeongcheon extract was 1% by weight, and after 48 hours, the final pH value was 5.61 to 5.70, which was slightly smaller than 0.5% by weight, but decreased.
그러나 도 2c 및 2d에서 나타낸 것과 같이 홍경천 농도가 3 중량% 및 5 중량%로 높아지게 되면, 초기 pH 6.15 및 6.13에서 48시간 후에는 5.95 내지 6.00, 6.04 내지 6.11로 유산균 종류에 따라 다소 차이가 있지만, 발효 전과 후의 pH의 차이가 없다는 것을 알 수 있다. However, as shown in Figures 2c and 2d when the honggyeongcheon concentration is increased to 3% by weight and 5% by weight, after 48 hours at the initial pH 6.15 and 6.13, but slightly different depending on the type of lactic acid bacteria to 5.95 to 6.00, 6.04 to 6.11, It can be seen that there is no difference in pH before and after fermentation.
상기 결과로부터 홍경천 3 중량% 이상에서는 배양시간의 증가에도 pH의 감소가 이루어지지 않고, 1 중량% 이하에서도 통상의 유산균 배양에서 관찰되는 pH의 감소는 나타나지 않음을 확인하였다.From the above results, it was confirmed that at 3 wt% or more of Rhodiola savona, the pH was not decreased even when the incubation time was increased, and even at 1 wt% or less, there was no decrease in pH observed in conventional lactic acid bacteria culture.
유산균별로 pH의 변화를 비교하면 Lactobacillus acidophillus 128(L1), Bifidiobacterium longum(B1), Bifidiobacterium breve(B2), Pediococcus pentosaceus(P0)의 pH가 다른 유산균주보다 상대적으로 큰 폭으로 감소하였음을 확인하였고, 홍경천 발효물 제조에 적합한 균주로 선정하였다.
Comparing the change of pH by lactic acid bacteria Lactobacillus acidophilus 128 (L1) , Bifidiobacterium longum (B1) , Bifidiobacterium It was confirmed that the pH of breve (B2) and Pediococcus pentosaceus (P0) was reduced significantly compared to other lactic acid strains, and was selected as a suitable strain for the preparation of fermented red pepper.
나. 홍경천 추출물 고형분 함량 및 유산균 종류에 따른 생균수 변화I. Changes in the Number of Viable Cells According to Solid Contents and Types of Lactic Acid Bacteria
유산균 10종 중 pH 변화가 상대적으로 크게 나타났던 유산균 4종(L. acidophillus 128, B. longum , B. breve , P. pentosaceus)을 다시 전 배양하고 균주의 성장능을 알아보기 위하여 고형분 함량 0.5 중량% 및 1 중량%의 홍경천 추출물에 유산균을 각각 1 중량%씩 접종하고 37 ℃에서 24 시간 발효한 후 생균수를 측정하여 그 결과를 표 2에 나타내었다. Four kinds of lactic acid bacteria ( L. acidophillus 128 , B. longum , B. breve , P. pentosaceus ) , which showed relatively large pH change among 10 kinds of lactic acid bacteria, were pre-incubated again and the content of 0.5 wt. 1% by weight of lactic acid bacteria were inoculated into% and 1% by weight of Honggyeongcheon extract, and fermented at 37 ° C. for 24 hours. The number of viable cells was measured and the results are shown in Table 2.
상기 표 1에 나타낸 바와 같이 홍경천 추출물을 L. acidophillus 128을 이용하여 배양한 결과 최초 접종 시 7.10*106 CFU/㎖에서 0.5 중량%에서는 1.2*103 CFU/㎖, 1 중량%에서는 1.3*102 CFU/㎖로 생균수가 오히려 감소하였다. 이는 다른 미생물과 비교했을 때 상대적으로 균수가 약간 높지만, 홍경천 추출물의 농도가 높을수록 생균수가 현저하게 줄어든 것을 알 수 있다. As shown in Table 1, the result of culturing Rhodiola sachalinensis using L. acidophillus 128 was 1.2 * 10 3 CFU / mL at 0.5 wt% at 7.10 * 10 6 CFU / mL at the first inoculation, and 1.3 * 10 at 1 wt%. The number of viable cells was rather reduced to 2 CFU / ml. This is a relatively high number of bacteria compared to other microorganisms, but it can be seen that the higher the concentration of Hongkyeongcheon extract, the number of viable bacteria is significantly reduced.
B. longum을 이용하여 배양한 결과 최초 생균수는 2.10*106 CFU/㎖로 0.5 중량%에서는 2.59*103 CFU/㎖, 1 중량%에서는 1.32*102 CFU/㎖였다. B. longum results first live cells were cultured using the 2.10 * 10 6, 0.5% by weight in CFU / ㎖ 2.59 * 10 3 CFU / ㎖, the 1% by weight was 1.32 * 10 2 CFU / ㎖.
B. breve을 이용하여 배양한 결과 생균수는 최초 접종 시 1.64*106 CFU/㎖에서 0.5 중량%에서는 4.40*102 CFU/㎖, 1 중량%에서는 8.95*10 CFU/㎖로 생균수가 점차 감소하였다. The viable cell count was 1.64 * 10 6 CFU / mL at 4.64 * 10 2 CFU / mL at 0.5% by weight and 8.95 * 10 CFU / mL at 1% by weight after incubation with breve . It was.
P. pentosaceus을 이용하여 발효한 결과 생균수는 1.50*106 CFU/㎖에서 0.5중량%에서는 2.01*102 CFU/㎖, 1 중량%에서는 1.29*10 CFU/㎖로 모든 유산균이 홍경천의 농도에 의존적으로 감소하는 것으로 나타났다.
Results number of viable cells by fermentation by using a P. pentosaceus is in a concentration of 1.50 * 10 6 in CFU / ㎖ 0.5% by weight of all the lactic acid bacteria to 1.29 * 10 CFU / ㎖ the 2.01 * 10 2 CFU / ㎖, 1% by weight honggyeongcheon It was found to decrease dependently.
홍경천과 홍삼의 유산균 발효특성을 비교하기 위하여, 제조예 1의 홍경천 추출물의 제조방법과 동일하게 홍삼 추출물을 제조하여 상기 각각의 미생물을 접종하여 37 ℃에서 24 시간 발효했을 때의 pH와 생균수의 변화를 표 3에 나타내었다.In order to compare the lactic acid bacteria fermentation characteristics of red ginseng and red ginseng, the red ginseng extract was prepared in the same manner as the preparation method of red ginseng extract of Preparation Example 1, and the pH and viable cell number of the microorganisms were inoculated and fermented at 37 ° C. for 24 hours. The change is shown in Table 3.
상기 표 3의 결과에 따르면 0.5 중량%의 홍삼 추출물에서 각각의 유산균을 접종하여 37 ℃에서 24 시간 발효했을 때, pH는 4.2 미만으로 약 2 이상 현저히 감소하며, 유산균의 생균수는 오히려 2로그 사이클로 증식하는 것을 확인할 수 있었다. 이러한 홍삼 추출물의 유산균 발효와 비교할 때, 홍경천 추출물의 발효는 홍경천의 항균작용으로 인하여 유산균의 생육이 크게 저해되고, 이로 인하여 유산균 또는 유산균에서 분비되는 효소에 의한 홍경천의 유용성분의 생물전환 효과가 홍경천 단독 발효에서는 극히 미미할 것으로 예상되었다. According to the results of Table 3, when inoculated with each lactic acid bacteria in 0.5% by weight of red ginseng extract and fermented at 37 ° C. for 24 hours, the pH was significantly decreased by about 2 or more to less than 4.2, and the viable cell count of lactic acid bacteria was rather 2 log cycles. Proliferation was confirmed. Compared with lactic acid bacteria fermentation of red ginseng extract, fermentation of red ginseng extract is greatly inhibited the growth of lactic acid bacteria due to the antimicrobial activity of the red ginseng, thereby the bioconversion effect of the useful components of red ginseng by enzymes secreted from lactic acid bacteria or lactic acid bacteria In single fermentation it was expected to be minimal.
다만, 상기 표 2의 결과에서 나머지 미생물에 비해 24시간 배양에 따른 잔존 생균수가 높은 Lactobacillus acidophillus 128을 선택하여 다음 실험에 이용하였다.
However, in the results of Table 2, Lactobacillus higher residual viable cell number after 24 hours culture than the remaining microorganisms acidophilus 128 was selected and used in the next experiment.
제조예Manufacturing example 2: 2: 홍경천Honggyeongcheon 발효물의Fermented 제조 Produce
가. 홍경천 추출물의 흡착제 처리end. Adsorbent Treatment of Rhodiola sachalinensis Extract
홍경천 추출물의 흡착제 처리에 사용한 11 종의 흡착제의 특성 및 응용분야를 정리하여 표 4에 나타내었다.Table 4 summarizes the characteristics and application fields of the 11 types of adsorbents used in the adsorbent treatment of Hong Kyungcheon extract.
(활성탄)Active carbon
(Activated carbon)
(활성백토)Clay activated
(Active clay)
(산성백토)Acid clay
(Acidic clay)
(제올라이트)Zeolite
(Zeolite)
(규조토)Diatom earth
(Diatomaceous earth)
(벤토나이트)Bentonite
(Bentonite)
제조예 1의 홍경천 열수 추출물(1% 고형물 함량, pH6.46) 100 ml에 11 종의 흡착제를 각각 50 g씩 처리하고 여과한 여액의 pH 및 고형분 함량을 측정하여 표 5에 나타내었다. 50 g of 11 adsorbents were respectively prepared in 100 ml of hot water extract (1% solids content, pH6.46) of Preparation Example 1, and the pH and solids content of the filtrate were measured and shown in Table 5.
흡착제absorbent
(활성탄)Active carbon
(Activated carbon)
(활성백토)Clay activated
(Active clay)
(산성백토)Acid clay
(Acidic clay)
(제올라이트)Zeolite
(Zeolite)
(규조토)Diatom earth
(Diatomaceous earth)
(벤토나이트)Bentonite
(Bentonite)
표 5에서 볼 수 있듯이, 초기 1% 고형물량의 홍경천 추출물의 경우 4.10의 pH를 나타내었으나, 흡착제를 처리한 후 여과한 여액의 pH는 활성탄, 활성백토, 산성백토, Dowex MWA-1, Amberlite IRC-50 등을 처리시에는 3.01~3.96로 낮아지는 반면 Aluminum oxide, Diaion HP-2MG, Zeolite, 규조토, 벤토나이트, Amberlite XAD-4 등을 처리한 경우에는 4.46~9.31로 높아지는 경향을 나타내었다. 특히 Zeolite의 경우 급격한 pH 변화를 나타내었다. As can be seen from Table 5, the initial 1% solids content of Honggyeongcheon extract showed a pH of 4.10, but the pH of the filtrate filtered after adsorbent treatment was activated carbon, activated clay, acidic clay, Dowex MWA-1, Amberlite IRC. When -50 and the like were lowered to 3.01 ~ 3.96, they increased to 4.46 ~ 9.31 when aluminum oxide, Diaion HP-2MG, Zeolite, diatomaceous earth, bentonite and Amberlite XAD-4 were treated. In particular, zeolite showed a sharp pH change.
고형물량의 경우에도 흡착제의 종류에 따라 흡착제 처리후 큰 변화를 나타내어 Amberlite XAD-4 처리시에는 오히려 2배 정도 증가한 반면 활성탄, Dowex MWA-1, Diaion HP-2MG를 처리했을 경우 40~50% 정도 감소하였다. 이러한 고형물량 감소는 향후 수율이나 주요활성 성분의 감소로 이어질 수 있어 바람직하지 못한 결과로 판단되었다.
In the case of solids, there was a big change after adsorbent treatment depending on the type of adsorbent, which was about 2 times increased when treated with Amberlite XAD-4, whereas about 40-50% when activated carbon, Dowex MWA-1, and Diaion HP-2MG were treated. Decreased. Such a decrease in solid content may lead to a decrease in yield or main active ingredients in the future, which is considered to be an undesirable result.
나. 홍경천 추출물 여액의 발효I. Fermentation of Rhodiola saline Extract Filtrate
상기 가.에서 얻은 흡착처리 여액을 먼저 유산균 발효를 위한 초기 pH인 6.5수준으로 조정하고, 제조예 1의 다.와 동일하게 Lactobacillus acidophillus 128을 접종하여 발효시킨 결과를 표 6에 나타내었다.Adsorption filtrate obtained in A. was first adjusted to 6.5, the initial pH for lactic acid bacteria fermentation, and Lactobacillus in the same manner as in Preparation Example 1. acidophilus Table 6 shows the result of fermentation by inoculation.
함량 (%)content (%)
흡착제로 처리한 후 발효시킨 홍경천 추출물Fermented Honggyeongcheon Extract after Treatment with Adsorbent
(활성탄)Active carbon
(Activated carbon)
(활성백토)Clay activated
(Active clay)
(산성백토)Acid clay
(Acidic clay)
(제올라이트)Zeolite
(Zeolite)
(규조토)Diatom earth
(Diatomaceous earth)
(벤토나이트)Bentonite
(Bentonite)
각 흡착제별로 처리후 여과한 홍경천 추출물의 pH를 유산균 발효를 위한 초기 pH인 6.5로, 고형물 함량을 1% 수준으로 재조정한 다음 유산균을 접종하고 37℃에서 48시간 발효시킨 후 pH와 가용성 고형물 함량을 살펴본 결과는 표 6과 같다.The pH of honggyeongcheon extract filtered after treatment with each adsorbent was adjusted to 6.5, which is the initial pH for lactic acid bacteria fermentation, and the solids content was adjusted to 1% level, and then inoculated with lactic acid bacteria and fermented at 37 ° C for 48 hours. The results are shown in Table 6.
발효를 48시간 이후의 pH 변화를 살펴보면 흡착제를 처리하지 않은 홍경천 추출물의 경우 6.5의 pH를 나타내어 유산균을 접종하고 48 시간 발효시켰음에도 pH 변화가 없어 발효가 진행되지 않았음을 알 수 있었다.Looking at the pH change after 48 hours of fermentation, it was found that the fermentation process without the adsorbent exhibited a pH of 6.5, inoculated with lactic acid bacteria and fermented for 48 hours.
이에 비하여 활성탄, 산성백토, Dowex MWA-1, Diaion HP-2MG, 규조토 및 벤토나이트의 경우 발효에 의해 pH가 5.0 미만으로 떨어지는 것을 알 수 있었고, 활성백토, 알루미늄 옥사이드, 제올라이트, Amberlite IRC-50 및 XAD-4는 pH가 5.0 이상으로 발효가 충분히 이루어지지 않은 것을 확인할 수 있었다.
Compared with activated carbon, acid clay, Dowex MWA-1, Diaion HP-2MG, diatomaceous earth, and bentonite, the pH was lowered to below 5.0 by fermentation, and activated clay, aluminum oxide, zeolite, Amberlite IRC-50 and XAD. -4 was confirmed that the fermentation was not sufficiently made to pH 5.0 or more.
따라서 활성탄, 산성백토, Dowex MWA-1, Diaion HP-2MG, 규조토 및 벤토나이트 처리는 유산균 발효에 도움을 주는 것으로 판단하였으나, 활성탄, Dowex MWA-1 및 Diaion HP-2MG 처리는 홍경천 추출물의 고형분량을 현저히 감소시키므로, 산성백토 또는 벤토나이트가 홍경천 발효물 제조에 바람직한 흡착제로 추정되었다.
Therefore, activated carbon, acidic clay, Dowex MWA-1, Diaion HP-2MG, diatomaceous earth and bentonite treatment were found to help fermentation of lactobacillus. However, activated carbon, Dowex MWA-1 and Diaion HP-2MG treatment resulted in the solid content of Honggyeongcheon extract. Due to the significant reduction, acidic clay or bentonite was assumed to be the preferred adsorbent for the preparation of fermentation products.
실험예Experimental Example 2: 흡착제의 적정 처리량 확인 시험 2: Confirmation of proper throughput of adsorbent
상기 제조예 2에서 선택한 산성백토 및 벤토나이트의 처리량이 홍경천 추출물의 유산균 발효에 미치는 영향을 살펴보기 위하여 70% MeOH와 증류수로 1차 세척 처리한 흡착제를 홍경천 추출물(0.8%) 100 ml 당 1, 5, 10, 15, 20, 25, 30, 35 g 씩 처리하여 500rpm으로 하루 동안 흡착처리 시킨 후 여과한 배양액에 제조예 2와 같이 유산균 접종하고 48 시간 동안 발효시키면서 발효물의 pH 변화를 살펴본 결과를 도 3에 나타내었다.In order to examine the effect of the treatment of acidic clay and bentonite selected in Preparation Example 2 on the fermentation of lactobacillus of Honggyeongcheon extract, the adsorbent first washed with 70% MeOH and distilled
산성백토나 벤토나이트 처리에 의한 발효특성 개선 효과는 1 중량%의 고형물을 가진 홍경천 추출물을 기준으로 홍경천 추출물 100 중량부에 흡착제 1 중량부부터 효과가 있지만, 바람직하게는 5 중량부 이상, 더욱 바람직하게는 20 중량부 이상 첨가해야 충분한 발효개선 효과를 달성할 수 있고, 25 중량부를 초과하더라도 더 이상 발효개선 효과는 나타나지 않았다.
The effect of improving fermentation characteristics by acidic clay or bentonite treatment is effective from 1 part by weight of the adsorbent to 100 parts by weight of honggyeongcheon extract based on honggyeongcheon extract having a solid content of 1% by weight, preferably 5 parts by weight or more, and more preferably. The addition of 20 parts by weight or more can achieve a sufficient fermentation improvement effect, even if more than 25 parts by weight did not show a fermentation improvement effect anymore.
1 중량% 고형분의 홍경천 추출물 100 ml에 각각의 25 g의 산성백토, 벤토나이트와 Dowex MWA-1을 24시간 흡착처리한 후, 제조예 1의 다.와 동일하게 Lactobacillus acidophillus 128을 접종하여 유산균수의 변화를 48 시간 동안 확인하여 도 4에 나타내었다. 대조군으로 흡착제를 처리하지 않은 홍경천 추출물에 동일하게 유산균을 접종한 것을 사용하였다.100 ml of 1 wt% solid content of Honggyeongcheon extract was adsorbed for 24 hours on each of 25 g of acidic clay, bentonite and Dowex MWA-1, followed by Lactobacillus acidophillus in the same manner as in Preparation Example 1. The inoculation of 128 to confirm the change in the number of lactic acid bacteria for 48 hours is shown in Figure 4. As a control, the same inoculation of lactic acid bacteria was used in the Hongkyungcheon extract that was not treated with the adsorbent.
최초 접종량 3.1×106 CFU/㎖에서 산성백토 흡착 처리 후 홍경천의 유산균 발효의 경우 24시간 후 5.14×105 CFU/㎖, 48시간 후 5.01×105 CFU/㎖ 로 약간 감소하였으며, Dowex MWA-1 흡착 처리시 발효 24시간 후 5.01×105 CFU/㎖, 48시간 후 5.85×105 CFU/㎖로, 벤토나이트 흡착 처리시 24시간 후 8.41×105 CFU/㎖, 48시간 후 8.52×105 CFU/㎖ 로 초기 균수가 다소 낮아진 것을 확인 할 수 있었다. 반면 흡착제 처리하지 않은 홍경천 추출물의 경우(대조군) 발효 초기부터 생균수가 크게 감소하기 시작하여 발효 2일째 생균수는 6.10×102 CFU/ml 수준까지 현저히 낮아진 것으로 나타나 흡착제 처리가 유산균의 증식과 발효를 촉진 시키는 효과가 있음을 알 수 있었다.
Lactic acid bacteria fermentation of Hongkyungcheon after acidic adsorption treatment at 3.1 × 10 6 CFU / mL was slightly decreased to 5.14 × 10 5 CFU / mL after 24 hours and 5.01 × 10 5 CFU / mL after 48 hours. 1 at 24 hours after fermentation at 5.01 × 10 5 CFU / mL, after 48 hours at 5.85 × 10 5 CFU / mL, at 24 hours after bentonite adsorption at 8.41 × 10 5 CFU / mL, after 48 hours at 8.52 × 10 5 It was confirmed that the initial bacterial count was somewhat lowered by CFU / ml. On the other hand, in the case of Hong Kyung-cheon extract without the adsorbent (control), the viable cell count decreased significantly from the beginning of fermentation, and the viable cell count decreased significantly to the level of 6.10 × 10 2 CFU / ml on the second day of fermentation. It can be seen that there is an effect promoting.
실험예Experimental Example 3: 3: 홍경천Honggyeongcheon 발효 전후의 Before and after fermentation 살리드로사이드Salidroside 배당체 및 Glycosides and 비배당체Non-glycoside 함량 비교 Content comparison
1 중량% 고형분의 홍경천 추출물 100 ml에 각각의 25 g의 산성백토 및 벤토나이트를 24시간 흡착처리한 후, 각각의 여액에 제조예 1의 다.와 동일하게 Lactobacillus acidophillus 128을 접종하여 48 시간 발효시켜 제조한 발효물의 가용성 총당, 산성 다당체 및 총페놀 함량을 홍경천 추출물과 비교하여 표 7에 나타내었다.After adsorbing 25 g of acidic clay and bentonite for 24 hours to 100 ml of 1 kg by weight of red ginseng extract, each filtrate was subjected to Lactobacillus acidophillus in the same manner as in Preparation Example 1. Soluble total sugar, acidic polysaccharide and total phenolic content of the fermentation product prepared by fermentation with 128 inoculation for 48 hours are shown in Table 7 in comparison with the extract of Honggyeongcheon.
총당 함량은 D-glucose를 표준 물질로 하여 phenol-sulfuric acid법으로 측정하였으며, 산성당 함량은 D-galacturonic acid를 표준 물질로 하여 m-hydroxydiphenyl법으로, 폴리페놀 화합물의 함량은 페놀성 물질이 phosphomolybdic acid 와 반응하여 청색을 나타내는 것을 이용한 Folin Denis법에 따라 gallic acid를 표준물질로 하여 비색법으로 측정하였다The total sugar content was measured by phenol-sulfuric acid method using D-glucose as a standard substance, and the acidic sugar content was m-hydroxydiphenyl method using D-galacturonic acid as standard substance, and the content of polyphenol compound was phosphomolybdic by phenolic substance. According to the Folin Denis method which reacts with acid and shows blue color, gallic acid was measured by colorimetric method.
초기 홍경천 추출물의 총당 함량은 75.97%, 산성다당체 함량은 26.16%, 총페놀 함량은 20.12% 수준이었으나 흡착제 처리시 총당과 산성당은 크게 변화가 없는 반면 총페놀 화합물량은 다소 감소하는 결과를 나타내었다. 이러한 결과는 흡착처리시 색소 등 총페놀화합물 함량에 영향을 미치는 성분이나 일부 페놀성화합물이 흡착되어 제거된 것에 기인하는 것으로 판단되었다. The total sugar content of the early red ginseng extract was 75.97%, the acid polysaccharide content was 26.16%, and the total phenol content was 20.12%, but the total phenolic and acidic sugars did not change significantly, but the total phenolic compound content decreased slightly. . These results were judged to be due to the adsorption and removal of some phenolic compounds and components that affect the total phenolic compound content such as pigments.
반면 유산균 발효시에는 대체로 총당과 산성다당체 함량은 감소하고 총페놀 화합물 함량은 다소 증가하는 경향을 나타내었다. 이와 같은 당류의 감소는 당류가 유산균 증식을 위한 영양원으로 소비된 반면 페놀화합물의 경우 이전의 연구와 마찬가지로 발효에 의해 가용성 페놀화합물 함량의 증가로 나타난 것으로 판단되었다.
On the other hand, when the lactic acid bacteria fermented, the total sugar and acid polysaccharide contents were generally decreased and the total phenolic compound contents were slightly increased. The decrease in sugars was thought to be due to the increase in the content of soluble phenolic compounds by fermentation as in the previous studies, while sugars were consumed as a nutrient for lactic acid bacteria growth.
실험예Experimental Example 4: 4: 홍경천Honggyeongcheon 발효 전후의 Before and after fermentation 살리드로사이드Salidroside 배당체 및 Glycosides and 비배당체Non-glycoside 함량 비교 Content comparison
1 중량% 고형분의 홍경천 추출물 100 ml에 각각의 25 g의 산성백토, 벤토나이트, Dowex MWA-1 및 Diaion HP-2MG로 24시간 흡착처리한 후, 각각의 여액에 제조예 1의 다.와 동일하게 Lactobacillus acidophillus 128을 접종하여 48 시간 발효시킨 후, 발효 전의 흡착제로 처리하여 얻은 여액과 발효물의 활성성분을 TLC와 HPLC로 분석하였다.100 ml of 1 wt.% Solid content of Honggyeongcheon extract was adsorbed with 25 g of acidic clay, bentonite, Dowex MWA-1 and Diaion HP-2MG for 24 hours, and then the filtrate was prepared in the same manner as in Preparation Example 1 Lactobacillus acidophilus After inoculating 128 and fermenting for 48 hours, the filtrate obtained by treatment with adsorbent before fermentation and the active ingredients of the fermentation were analyzed by TLC and HPLC.
TLC 분석을 위해 Silica gel TLC plate (60F254, Merck, Germany)에 시료를 점적하여 chloroform/methanol/H20 (70:30:4)로 전개한 후 30% H2SO4시약을 분무하여 105 ℃에서 30분간 발색시켜 각 성분의 위치를 확인하였고, 그 결과를 도 5에 나타내었다. 표준물질로 살리드로사이드(S1) 및 살리드로사이드의 비배당체로 ρ-tyrosol(S2)을 사용하였다.
Samples were deposited on Silica gel TLC plates (60F 254 , Merck, Germany) for TLC analysis, developed with chloroform / methanol / H20 (70: 30: 4) and sprayed with 30% H 2 SO 4 reagent at 105 ° C. Color development was carried out for 30 minutes to confirm the position of each component, the results are shown in FIG. Salicide side (S1) as a standard and ρ-tyrosol (S2) were used as a non-glycoside of salicide side.
HPLC분석은 Waters SunfireTM C18 컬럼과 이동상으로 20% 메탄올 (v/v)용액을 이용하여 수행하였으며 시료 주입량은 20 ㎕, 용매의 전개 속도는 1 ㎖/min로 하고, UV 검출기를 이용하여 278 ㎚에서 측정하였다. 표준물질로는 살리드로사이드(S), 그리고 살리드로사이드의 비배당체로 ρ-tyrosol(SH)을 사용하였다.HPLC analysis was Waters Sunfire TM The C18 column and the mobile phase were carried out using a 20% methanol (v / v) solution. The sample injection amount was 20 µl, the solvent development rate was 1 ml / min, and measured at 278 nm using a UV detector. Salidroside (S) was used as a standard, and ρ-tyrosol (SH) was used as a non-glycoside of salidroside.
도 6a는 살리드로사이드(S) 및 그 비배당체 표준품(SH)의 HPLC 크로마토그램, 도 6b는 산성백토로 흡착처리하기 전의 홍경천 추출물의 크로마토그램, 도 6c는 산성백토로 흡착처리한 홍경천 추출물 여액의 크로마토그램 그리고, 도 6d는 산성백토로 흡착처리한 홍경천 추출물 여액을 48시간 발효시킨 발효물의 크로마토그램이다. 크로마토그램은 산성백토 처리의 경우만 나타내었고, 다른 흡착제를 처리한 경우는 살리드로사이드 및 살리드로사이드 비배당체의 함량을 도 7에 정리하여 나타내었다. 상기 도 7에서 Con은 홍경천 추출물, 1B는 산성백토 흡착 여액, 1A는 산성백토 흡착 여액의 발효물, 2B는 Dowex MWA-1 흡착 여액, 2A는 Dowex MWA-1 흡착 여액의 발효물, 3B는 Diaion HP-2MG 흡착 여액, 3A는 Diaion HP-2MG 산성백토 흡착 여액의 발효물, 4B는 벤토나이트 흡착 여액, 4A는 벤토나이트 흡착 여액의 발효물을 나타낸다.
6a is an HPLC chromatogram of salidroside (S) and its non-glycoside standard (SH), FIG. 6b is a chromatogram of Honggyeongcheon extract before adsorptive treatment with acidic clay, and FIG. 6c is a Honggyeongcheon extract filtrate adsorbed with acidic clay Chromatogram of Fig. 6d is a chromatogram of a fermentation product obtained by fermenting a filtrate of Hongkyungcheon extract filtrate adsorbed with acidic clay for 48 hours. The chromatogram was shown only in the case of acidic clay treatment, and in the case of treatment with other adsorbents, the contents of the salicide side and the salicide side non-glycoside are shown in FIG. 7. In FIG. 7, Con is a Hong Kyungcheon extract, 1B is an acid clay adsorbed filtrate, 1A is an acid clay adsorbed filtrate, 2B is a Dowex MWA-1 adsorbed filtrate, 2A is a fermented product of Dowex MWA-1 adsorbed filtrate, 3B is Diaion HP-2MG adsorption filtrate, 3A represents a fermentation product of Diaion HP-2MG acid clay adsorption filtrate, 4B is a bentonite adsorption filtrate, 4A represents a fermentation product of a bentonite adsorption filtrate.
상기 TLC 및 HPLC 결과를 보면, 주요 지표성분중의 하나인 salidroside의 경우 산성백토, Dowex MWA-1, 벤토나이트 처리시에는 홍경천 추출물과 거의 유사한 함량을 나타낸 반면 Dianion HP-20M 처리시에는 여액의 salidroside 함량이 감소됨을 확인할 수 있었다. Salidroside의 aglycon 형태인 tyrosol의 경우, 산성백토, Dowex MWA-1, 벤토나이트 처리시에 유산균 발효시에 발효전에 비해 다소 증가하는 경향을 나타내었다. 특히 산성백토 처리시에 흡착처리하지 않은 홍경천 추출물과 거의 유사한 salidroside 함량을 나타내어 흡착으로 인한 지표성분 손실이 가장 낮은 것으로 나타났으며 발효로 인한 tyrosol로의 전환 경향 역시 가장 뚜렷하게 나타남을 알 수 있었다.
TLC and HPLC results showed that salidroside, one of the major indicators, had almost the same content as that of Hongkyungcheon extract when treated with acidic clay, Dowex MWA-1, and bentonite, whereas salidroside content of filtrate when treated with Dianion HP-20M. It was confirmed that this is reduced. In the case of salidroside aglycon type tyrosol, acidic clay, Dowex MWA-1 and bentonite were slightly increased compared to before fermentation of lactic acid bacteria. In particular, the acidic clay showed the lowest salidroside content, which was almost the same as that of non-adsorption Hongkyeongcheon extract, which showed the lowest loss of surface components due to adsorption, and also showed the tendency of conversion to tyrosol due to fermentation.
일반적으로 유산균 등을 활용한 천연소재의 발효시 배당체 형태의 지표성분을 비배당체 형태로 전환시켜 체내 흡수율과 기능성을 증진시키는 사실로 미루어 볼 때 이러한 결과는 홍경천 기능성 성분의 기능성과 흡수율을 증진시키는 효과를 나타내 줄 것으로 기대되었다.
In general, when the fermentation of natural materials using lactic acid bacteria and the like to convert the glycosides to the non-glycoside form to increase the absorption and functionality in the body, these results have the effect of enhancing the functionality and absorption rate of the functional components of Honggyeongcheon It was expected to indicate.
하기에 본 발명의 홍경천 발효물을 함유하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.Hereinafter, an example of the preparation of the composition containing the fermentation of Honggyeongcheon of the present invention will be described.
제제예Formulation example 1. One. 산제의Sanje 제조 Produce
실험예 2의 산성백토로 처리한 홍경천 발효물 분말 20 mg20 mg of Hongkyungcheon fermented powder treated with acid clay of Experimental Example 2
유당 100 mg
탈크 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.
The above components are mixed and filled in airtight bags to prepare powders.
제제예Formulation example 2. 정제의 제조 2. Preparation of tablets
실험예 2의 산성백토로 처리한 홍경천 발효물 분말 10 mg10 mg of Hongkyungcheon fermented powder treated with acid clay of Experimental Example 2
옥수수전분 100 mg
유당 100 mg
스테아린산 마그네슘 2 mg
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Preparation of capsules
실험예 2의 산성백토로 처리한 홍경천 발효물 분말 10 mg10 mg of Hongkyungcheon fermented powder treated with acid clay of Experimental Example 2
결정성 셀룰로오스 3 mg
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
실험예 2의 산성백토로 처리한 홍경천 발효물 분말 20 mg20 mg of Hongkyungcheon fermented powder treated with acid clay of Experimental Example 2
이성화당 10 g10 g per isomer
만니톨 5 g5 g mannitol
정제수 적량Purified water quantity
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.
Each component was added to purified water in accordance with the conventional liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water and adjusted to 100 as a whole. To prepare a liquid agent.
제제예Formulation example 6. 건강기능식품의 제조 6. Manufacture of health functional foods
실험예 2의 산성백토로 처리한 홍경천 발효물 분말 1,000 mg1,000 mg of Hongkyungcheon fermented powder treated with acid clay of Experimental Example 2
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate
비타민 E 1.0 mgVitamin E 1.0 mg
비타민 B1 0.13 mgVitamin B1 0.13 mg
비타민 B2 0.15 mg0.15 mg of vitamin B2
비타민 B6 0.5 mgVitamin B6 0.5 mg
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 mg
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 mgNicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 mgCalcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 mg1.75 mg of ferrous sulfate
산화아연 0.82 mg0.82 mg of zinc oxide
탄산마그네슘 25.3 mgMagnesium carbonate 25.3 mg
제1인산칼륨 15 mgPotassium monophosphate 15 mg
제2인산칼슘 55 mgSecondary calcium phosphate 55 mg
구연산칼륨 90 mgPotassium citrate 90 mg
탄산칼슘 100 mg
염화마그네슘 24.8 mgMagnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강기능식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.
Although the composition ratio of the above-mentioned vitamin and mineral mixtures is a composition that is relatively suitable for the health functional food, the composition is mixed in a preferred embodiment, but the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health functional food manufacturing method. Then, the granules may be prepared and used for preparing the nutraceutical composition according to a conventional method.
제제예Formulation example 7. 기능성 음료의 제조 7. Preparation of Functional Beverages
실시예 3의 홍경천 발효물 분말 1,000 mg1,000 mg of honggyeongcheon fermented product powder of Example 3
구연산 1,000 mgCitric acid 1,000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 mLPurified water was added to the flask to obtain a total of 900 mL
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85 ℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 기능성 음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the functional beverage composition of the invention.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (10)
상기 흡착제에 흡착되지 않은 여액에 유산균을 접종하여 발효시키는 단계를 포함하는 홍경천 발효물의 제조방법.
Treating the Hong Kyungcheon extract with at least one adsorbent selected from acidic clay, bentonite, diatomaceous earth, activated carbon and weakly basic anion exchange resin; And
Inoculating the lactic acid bacteria in the filtrate that is not adsorbed to the adsorbent and fermentation method comprising the step of fermentation.
The method of claim 1, wherein the adsorbent is acid clay or bentonite.
2. The method of claim 1, wherein the weakly basic anion exchange resin is Dowex MWA-1.
The method according to claim 1, wherein 5 to 60 parts by weight of an adsorbent is mixed with respect to 100 parts by weight of the extract of Honggyeongcheon.
The method of claim 1, wherein the solid content of the honggyeongcheon extract is 0.1 to 10% by weight.
According to claim 1, wherein the lactic acid bacteria Lactobacillus genus, Bifidobacterium genus and Pediococcus genus Lactobacillus, characterized in that any one or more lactic acid bacteria selected from lactic acid bacteria manufacturing method.
According to claim 6, The lactic acid bacteria Lactobacillus ashdophyllus [KCTC 2182], Bifidobacterium long gum [ATCC 15707], Bifidobacterium brevis [ATCC 15700] and Pediococcus pentosaceus [KCCM 11088P Method for producing a fermentation product of Honggyeongcheon, characterized in that any one or more lactic acid bacteria selected from.
The method of claim 1, wherein the fermentation is carried out at 25 to 40 ℃ 24 to 96 hours, characterized in that the manufacturing method of the fermented Honggyeongcheon.
A fermentation product obtained by inoculating fermentation of Honggyeongcheon extract with lactic acid bacteria in a filtrate treated with one or more adsorbents selected from acidic clay, bentonite, diatomaceous earth, activated carbon and weakly basic anion exchange resin, and the total weight of salidroside glycoside and nonglycoside Honggyeongcheon fermentation, characterized in that the content of non-glycosides in 30 to 100 parts by weight.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110126414 | 2011-11-30 | ||
KR20110126414 | 2011-11-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130061046A true KR20130061046A (en) | 2013-06-10 |
KR101348978B1 KR101348978B1 (en) | 2014-01-16 |
Family
ID=48492180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120098953A KR101348978B1 (en) | 2011-11-30 | 2012-09-06 | Preparation method for fermented rhodiola rosea using absorbents |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101348978B1 (en) |
CN (1) | CN103131730B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103710412A (en) * | 2013-12-11 | 2014-04-09 | 福州大学 | Process for synthesizing salidroside under catalysis of beta-glucosidase cross-linked aggregates |
CN108057038A (en) * | 2018-02-24 | 2018-05-22 | 上海中医药大学附属曙光医院 | A kind of composition for treating liver fibrosis and its application |
KR20230061819A (en) * | 2021-10-29 | 2023-05-09 | 강금석 | Method for manufacturing fermented complex extract with anti-aging and whitening activity |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105861600A (en) * | 2016-04-13 | 2016-08-17 | 河南省商业科学研究所有限责任公司 | Preparation method of Rhodiola rosea extract for effectively promoting sleep and enhancing immunity |
CN105996025A (en) * | 2016-05-10 | 2016-10-12 | 天津膳方缘科技有限公司 | Preparing method for rhodiolae root fermentation liquor |
JP2018193341A (en) * | 2017-05-19 | 2018-12-06 | 共栄化学工業株式会社 | Plant fermentation product |
CN112472634B (en) * | 2019-09-12 | 2024-06-21 | 上海瑞帝安生物科技有限公司 | Rhodiola rosea extract, and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0179088B1 (en) * | 1995-12-21 | 1999-03-20 | 백운화 | Composition containing rhodiola sachalinesis extract for prophylaxis and treatment of diabetes mellitus |
CN101095690A (en) * | 2006-06-30 | 2008-01-02 | 成都华高药业有限公司 | Rhodiola sacra extractive, medicinal composition containing the same, method for preparing the same and the use thereof |
CN101974045B (en) * | 2010-10-19 | 2013-11-20 | 康美药业股份有限公司 | Method for preparing salidroside |
KR101381112B1 (en) * | 2011-11-30 | 2014-04-14 | 한국식품연구원 | Preparation method for fermented rhodiola rosea using red ginseng and composition for fatigue recovery and improvement of exercise performance comprising the fermented rhodiola rosea |
-
2012
- 2012-08-30 CN CN201210316408.0A patent/CN103131730B/en active Active
- 2012-09-06 KR KR1020120098953A patent/KR101348978B1/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103710412A (en) * | 2013-12-11 | 2014-04-09 | 福州大学 | Process for synthesizing salidroside under catalysis of beta-glucosidase cross-linked aggregates |
CN103710412B (en) * | 2013-12-11 | 2016-02-24 | 福州大学 | Beta-glucosidase cross-linked aggregates catalyzes and synthesizes the technique of rhodioside |
CN108057038A (en) * | 2018-02-24 | 2018-05-22 | 上海中医药大学附属曙光医院 | A kind of composition for treating liver fibrosis and its application |
KR20230061819A (en) * | 2021-10-29 | 2023-05-09 | 강금석 | Method for manufacturing fermented complex extract with anti-aging and whitening activity |
Also Published As
Publication number | Publication date |
---|---|
KR101348978B1 (en) | 2014-01-16 |
CN103131730B (en) | 2014-09-10 |
CN103131730A (en) | 2013-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101348978B1 (en) | Preparation method for fermented rhodiola rosea using absorbents | |
KR101381112B1 (en) | Preparation method for fermented rhodiola rosea using red ginseng and composition for fatigue recovery and improvement of exercise performance comprising the fermented rhodiola rosea | |
KR20170061959A (en) | Preparation method of fermented ginseng and fermented black-red ginseng with active ginsenoside heightening rate absorption | |
KR20110027247A (en) | Method for manufacturing whole soybean milk containing high content of active isoflavon | |
KR101909999B1 (en) | NOVEL STRAIN OF Leuconostoc mesenteroides AND COMPOSITION FOR PREVENTING OR TREATING OF CANCER USING THE SAME | |
KR20100074382A (en) | Fermented drinks of ginseng and preparation method thereof | |
KR101651082B1 (en) | A Composition Comprising the Fermentate of Puerariae Radix extract for protecting liver damage | |
KR102350102B1 (en) | Composition for anti-inflammation comprising extract of fermented red ginseng with improved antioxidant activity as effective component | |
KR20160126591A (en) | Method of producing ginseng fermented extract, Ginseng fermented extract produced by the same and Health functional foods comprising the same | |
KR102452957B1 (en) | Composition for preventing or treating clostridioides difficile infection comprising combination of probiotics | |
KR101892615B1 (en) | Lactobacillus sakei 2-6-4 and its use | |
KR101267886B1 (en) | composition using Mycoleptodonoides aitchisonii for preventing and treating dyslipidemia in diabetes | |
KR101482044B1 (en) | Food composition comprising fermented product of Pleuropterus multiflorus and ginger for alleviating or preventing degenerative brain disorder and method of producing the same | |
KR20100008831A (en) | Anti-cancer composition comprising a culture fluid of lactobacillus casei as an effective component | |
KR102042151B1 (en) | A composition as a prebiotic for improving intestinal microflora containing extract from pepper leaves | |
KR102048434B1 (en) | A composition as a prebiotic for improving intestinal microflora containing High-molecular fraction from radish leave | |
KR20180120933A (en) | Novel lactic acid bacteria strain leuconostoc mesenteroides cjnu 0041 and compositions for preventing, treating and improving colitis diseases comprising broccoli product fermented by leuconostoc mesenteroides cjnu 0041 | |
KR101915058B1 (en) | NOVEL STRAIN OF Leuconostoc mesenteroides AND COMPOSITION FOR PREVENTING OR TREATING OF INFLAMMATORY DISEASE USING THE SAME | |
KR101470347B1 (en) | A Composition Comprising the Fermentate of Scutellariae Radix extract for protecting liver damage | |
KR20200075724A (en) | A composition as a prebiotic for improving intestinal microflora containing extract from radish leave | |
KR102620909B1 (en) | Novel Lactiplantibacillus plantarum SKO-001 and use thereof | |
KR20040071953A (en) | Novel microorganism producing 1-deoxynojirimycin and its composition containing the same | |
KR101740502B1 (en) | Pharmaceutical composition for relieving hangover which comprises extract of Cedrela sinensis A. Juss. as an active component | |
KR102299687B1 (en) | Composition for improving anticancer efficacy of sorafenib containing polygonum cuspidatum extract as an active ingredient | |
KR102079794B1 (en) | Novel Enterococcus faecium microorganism and its use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170102 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180423 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20200102 Year of fee payment: 7 |